PORTLAND, Ore.--(BUSINESS WIRE)--Bioject Medical Technologies Inc. (Nasdaq:BJCT), a leading developer of needle-free drug delivery systems, today announced that it has entered into a three-year supply agreement with Merck Serono, a division of Merck KGaA of Darmstadt, Germany, for the delivery of the cool.click™ and Serojet™ spring-powered needle-free device for use with Merck Serono’s recombinant human growth hormone drugs.
